Valuation: Indivior PLC

Market Cap 4.85B 4.24B 3.91B 3.62B 6.89B 463B 6.98B 46.62B 18.17B 227B 18.22B 17.82B 786B P/E 2026 *
12.6x
P/E 2027 * 11.1x
Enterprise Value 4.91B 4.29B 3.95B 3.67B 6.97B 468B 7.06B 47.14B 18.37B 230B 18.43B 18.02B 795B EV / Sales 2026 *
3.9x
EV / Sales 2027 * 3.4x
Free-Float
97.19%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%+4.78% - - 4.85B
-1.14%-0.67%+53.72%+157.69% 1,082B
-1.41%+1.83%+66.23%+59.28% 633B
-2.42%+0.56%+34.59%+85.12% 461B
-0.26%+1.37%+31.00%+23.05% 338B
-2.46%-1.52%+36.42%+32.77% 299B
-2.20%-0.93%+27.50%+40.62% 291B
-1.77%+0.99%-28.85%-41.41% 222B
-2.06%+2.26%+22.87%+62.23% 202B
-1.26%+1.35%+15.98%+67.80% 163B
Average -0.60%+4.45%+28.83%+54.13% 410.27B
Weighted average by Cap. -0.46%+5.43%+39.61%+78.91%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.01B 940M 1.79B 120B 1.81B 12.08B 4.71B 58.87B 4.72B 4.62B 204B 1.31B 1.14B 1.05B 977M 1.86B 125B 1.88B 12.56B 4.9B 61.21B 4.91B 4.8B 212B
Net income 414M 362M 334M 310M 589M 39.53B 596M 3.98B 1.55B 19.4B 1.56B 1.52B 67.17B 473M 413M 381M 353M 672M 45.1B 680M 4.54B 1.77B 22.13B 1.78B 1.74B 76.63B
Net Debt 54.5M 47.62M 43.87M 40.71M 77.4M 5.2B 78.37M 524M 204M 2.55B 205M 200M 8.83B -403M -352M -325M -301M -573M -38.48B -580M -3.88B -1.51B -18.88B -1.51B -1.48B -65.37B
Logo Indivior PLC
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-